Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minetta C Liu

Showing results (101-110 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2019
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast CancerRoisin M Connolly, Jeffrey P Leal, Lilja Solnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanomaGeorge Ansstas, Karam Khaddour, Sumedha Sudhaman, et al.
Medrxiv : the Preprint Server for Health Sciences|September 2, 2025
Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative StudiesNeil Carleton, Alexander C Chang, Fangyuan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Annals of Surgery|September 26, 2025
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort StudyKoji Ando, Atsushi Hamabe, Yoshiaki Nakamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerAyca Gucalp, Sara Tolaney, Steven J Isakoff, et al.
NAR Cancer|June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy responseKevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.
Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
Pageof 16

Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2019
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast CancerRoisin M Connolly, Jeffrey P Leal, Lilja Solnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanomaGeorge Ansstas, Karam Khaddour, Sumedha Sudhaman, et al.
Medrxiv : the Preprint Server for Health Sciences|September 2, 2025
Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative StudiesNeil Carleton, Alexander C Chang, Fangyuan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Annals of Surgery|September 26, 2025
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort StudyKoji Ando, Atsushi Hamabe, Yoshiaki Nakamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerAyca Gucalp, Sara Tolaney, Steven J Isakoff, et al.
NAR Cancer|June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy responseKevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.
Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
Pageof 16